SPOTLIGHT: Zyrtec-D gets cleared for OTC sale


Prescription Zyrtec-D is dead! Long live Zyrtec-D! The FDA will allow Johnson & Johnson--which owns over-the-counter rights to the allergy med--to sell Zyrtec-D without a prescription, a move that will undoubtedly cut into Pfizer's sales of the prescription form. Report

Suggested Articles

Pfizer's diagnosis-focused launch strategy for Vyndaqel and Vyndamax is paying off with the meds reaching thousands of patients already.

A phase 1 study of the Inlyta-Keytruda regimen, which bears a first-line nod for kidney cancer, got the ax along with several Bavencio tests.

With its Eli Lilly-partnered Olumiant nearing filing in atopic dermatitis, Incyte's other JAK med Jakafi is also looking for a win in that indication.